MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety,
pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of
therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1), plus activating agent, AP1903, in
patients with castrate resistant prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Bellicum Pharmaceuticals
Collaborators:
Baylor College of Medicine M.D. Anderson Cancer Center Memorial Hermann Hospital The University of Texas Health Science Center, Houston